In last trading session, Immunome Inc (NASDAQ:IMNM) saw 0.45 million shares changing hands with its beta currently measuring 1.90. Company’s recent per share price level of $8.77 trading at -$0.16 or -1.79% at ring of the bell on the day assigns it a market valuation of $742.60M. That closing price of IMNM’s stock is at a discount of -204.45% from its 52-week high price of $26.70 and is indicating a premium of 4.33% from its 52-week low price of $8.39. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.68 million shares which gives us an average trading volume of 926.66K if we extend that period to 3-months.
For Immunome Inc (IMNM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.61 in the current quarter.
Immunome Inc (NASDAQ:IMNM) trade information
Upright in the red during last session for losing -1.79%, in the last five days IMNM remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $8.77 price level, adding 7.78% to its value on the day. Immunome Inc’s shares saw a change of -17.42% in year-to-date performance and have moved -6.10% in past 5-day. Immunome Inc (NASDAQ:IMNM) showed a performance of -15.67% in past 30-days. Number of shares sold short was 9.3 million shares which calculate 8.14 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 33 to the stock, which implies a rise of 73.42% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -162.26% in reaching the projected high whereas dropping to the targeted low would mean a loss of -162.26% for stock’s current value.
Immunome Inc (IMNM) estimates and forecasts
This year revenue growth is estimated to fall -32.90% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.16M for the same. And 6 analysts are in estimates of company making revenue of 515.67k in the next quarter. Company posted 3.83M and 1.03M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -48.48% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 18.54% while estimates for its earnings growth in next 5 years are of 16.33%.
Immunome Inc (NASDAQ:IMNM)’s Major holders
Insiders are in possession of 19.27% of company’s total shares while institution are holding 62.85 percent of that, with stock having share float percentage of 77.86%. Investors also watch the number of corporate investors in a company very closely, which is 62.85% institutions for Immunome Inc that are currently holding shares of the company. REDMILE GROUP, LLC is the top institutional holder at IMNM for having 4.89 million shares of worth $59.16 million. And as of 2024-06-30, it was holding 8.1579 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 4.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0257 of outstanding shares, having a total worth of $50.95 million.
On the other hand, Price (T.Rowe) Small Cap Stock Fund and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.96 shares of worth $17.16 million or 3.14% of the total outstanding shares. The later fund manager was in possession of 1.69 shares on Dec 31, 2024 , making its stake of worth around $14.84 million in the company or a holder of 2.71% of company’s stock.
